Workflow
新天药业(002873) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥249,216,213.05, representing a 16.10% increase compared to ¥214,656,599.98 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was ¥30,879,340.57, up 21.73% from ¥25,366,384.98 year-on-year[3] - Basic earnings per share increased by 18.08% to ¥0.1868, compared to ¥0.1582 in the same period last year[3] - The operating profit for the first quarter was CNY 34,639,863.10, up from CNY 30,472,241.92, reflecting a growth of 7.1% year-over-year[18] - The total comprehensive income for the first quarter was CNY 30,879,340.57, compared to CNY 25,366,384.98, marking an increase of 21.5%[18] Cash Flow - The net cash flow from operating activities decreased by 77.96% to ¥3,695,741.81, down from ¥16,766,677.68 in the previous year[6] - The cash flow from investment activities for Q1 2022 was ¥31,179,154.70, a significant recovery from -¥65,463,297.81 in the previous year[6] - The cash and cash equivalents at the end of the period amounted to CNY 144,358,114.14, compared to CNY 226,589,843.63 at the end of the previous year, a decrease of 36.3%[21] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,588,465,962.04, a 4.20% increase from ¥1,524,426,501.68 at the end of the previous year[3] - The total liabilities increased slightly to RMB 644,546,790.79 from RMB 633,983,091.90 at the beginning of the year[14] - The company's total equity attributable to shareholders increased by 6.01% to ¥943,919,171.25 from ¥890,443,409.78 at the end of the previous year[3] Research and Development - Research and development expenses surged by 178.79% to ¥3,589,480.60, compared to ¥1,287,534.50 in the previous year[6] - Research and development expenses increased significantly to RMB 3,589,480.60, compared to RMB 1,287,534.50 in the same quarter of the previous year, reflecting a growth of 179.3%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,944[8] - The company raised CNY 83,000,000.00 through borrowings, significantly higher than CNY 13,000,000.00 in the previous year, indicating a strategic move to enhance liquidity[21] Operating Costs - The total operating costs for the first quarter of 2022 were RMB 214,995,242.32, up 17.0% from RMB 183,991,577.13 in the previous year[16] - Accounts receivable stood at RMB 218,276,635.91, showing a slight decrease from RMB 222,775,435.76 at the beginning of the year[12] - Inventory levels increased to RMB 154,519,844.54 from RMB 118,770,773.96, indicating a growth of 30.2%[13] - The short-term borrowings rose to RMB 308,000,000.00 from RMB 268,342,558.34, reflecting a growth of 14.8%[13] Government Subsidies and Tax - The company received government subsidies amounting to ¥1,364,741.35, an increase of 78.13% from ¥766,142.44 in the previous year[6] - The company incurred a total tax expense of CNY 3,754,291.98, down from CNY 4,916,577.28, a reduction of 23.6% year-over-year[18]